All studies
Oncology · EHR and claims · US
Kong 2025
HR-positive HER2-negative advanced breast cancer
QBA performedITTSuperiorityAcademia, Industry2/5 disclosures
Comparisons
1
In the analysis
1
all comparisons pooled
Target trials
1
Emulations reported
1
2 treatments
Design and methods
- Estimand
- ITT
- Design hypothesis
- Superiority
- Matching / weighting
- IPTW and propensity-score matching
- Analysis method
- Weighted Cox proportional hazards model
- Missing data
- Not reported
- DAG
- No
- QBA
- Yes
Data and sample
- Data type
- EHR and claims
- Data sources
- Linked EHR and claims
- Geography
- US
- Eligible sample
- 3912
- Treated
- 106
- Control
- 3806
- Emulations
- 1
- Treatments compared
- 2
Transparency
- Protocol
- No pre-registration
- Preprint
- No preprint
- Data availability
- Unavailable
- Code availability
- Unavailable
- Conflicts of interest
- Declared: Industry
- COI institutions
- Aetion
- Funding
- Declared: Private
- Funders
- Aetion
The 0-5 count records which disclosures are present. It is not a quality score: a data link does not establish that the data are reusable.
Provenance
- Review key
- 2025_Kong_MONALEESA2
- DOI
- 10.57264/cer-2025-0026
- Affiliations
- Aetion; University of Pennsylvania; Emory University
- Sector
- Academia, Industry
- Target trials (study level)
- MONALEESA-2
- Registration
- NCT01958021